#### Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

#### WATSON PHARMACEUTICALS INC

Form 4

September 05, 2006

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

Check this box if no longer

January 31, Expires: 2005

**OMB APPROVAL** 

subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Estimated average burden hours per response...

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **BOYER ANDREW S** 

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

WATSON PHARMACEUTICALS

(Check all applicable)

INC [WPI]

(Last) (First) (Middle) 3. Date of Earliest Transaction

Director 10% Owner Other (specify

SVP, Generic Sales & Marketing

(Month/Day/Year)

09/01/2006

X\_ Officer (give title below)

C/O WATSON PHARMA. INC., 360 MOUNT KEMBLE

**AVENUE** 

4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year)

Applicable Line) \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

MORRISTOWN, NJ 07960

(City) (State) (Zip)

(Street)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

3. 4. Securities Execution Date, if TransactionAcquired (A) or Code Disposed of (D)

(Instr. 8)

5. Amount of Securities Beneficially Owned

7. Nature of Ownership Indirect Form: Direct Beneficial (D) or Ownership

(Instr. 4)

Indirect (I)

(Instr. 4)

Following Reported

(A) Price

Transaction(s) (Instr. 3 and 4)

Common

Stock 09/01/2006 (Restricted)

\$0 7.501 Α 5.834 Α

(D)

(Instr. 3, 4 and 5)

Amount

D

(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: WATSON PHARMACEUTICALS INC - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	orDerivative Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options to Purchase Common Stock (2)	\$ 25.64	09/01/2006		A	17,500		(3)	09/01/2016	Common Stock, par value \$0.0033	17,500

# **Reporting Owners**

Reporting Owner Name / Address	Relationships							
• 9	Director	10% Owner	Officer	Other				
BOYER ANDREW S C/O WATSON PHARMA, INC. 360 MOUNT KEMBLE AVENUE MORRISTOWN, NJ 07960			SVP, Generic Sales & Marketing					

### **Signatures**

/s/ANDREW S.

BOYER 09/01/2006
\*\*Signature of Reporting Date

\*\*Signature of Reporting
Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- These restricted shares of common stock, par value \$0.0033, were issued pursuant to the provisions of the Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc. (including, but not limited to, restrictions on transferability and certain forfeiture provisions concerning unvested restricted shares). The restricted shares vest (i) fifty percent on the second anniversary of the date of grant, and (ii) fifty percent on the fourth anniversary of the date of grant.
- (2) The options are to be incentive stock options to the extent permitted by law, and thereafter to be non-statutory stock options.
- (3) These stock options shall become exercisable in four equal annual installments commencing on September 1, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2